Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 11/20 | 0.37 |
| ▸ | LCK | P06239 | 6/20 | 0.37 |
| ▸ | SRC | P12931 | 6/20 | 0.37 |
| ▸ | CDK2 | P24941 | 3/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 2/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | WNT1 | P04628 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16682078 | 0.89 | CACNA1I (0.35) | RETLCKSRCCDK2CCNE1 | |
| SCHEMBL16675924 | 0.78 | RET (0.36) | RETLCKSRCCDK2BRD4 | |
| SCHEMBL16675945 | 0.78 | GSK3B (0.44) | CDK2GSK3B | |
| SCHEMBL16675902 | 0.77 | CCNA2 (0.38) | RETLCKSRCCDK2CCNA2 | |
| SCHEMBL16675896 | 0.77 | RET (0.37) | RETLCKSRCCDK2CCNE1 | |
| SCHEMBL16675899 | 0.76 | CCNA2 (0.40) | RETLCKSRCCDK2CCNA2 | |
| SCHEMBL16675919 | 0.74 | CCNA2 (0.40) | RETLCKSRCCDK2CCNA2 | |
| SCHEMBL16675929 | 0.73 | CCNA2 (0.39) | RETLCKSRCCDK2CCNA2 | |
| SCHEMBL16675915 | 0.73 | CCNA2 (0.37) | RETLCKSRCCDK2CCNA2 | |
| SCHEMBL16675912 | 0.72 | RET (0.39) | RETCDK2CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | ATP5F1A, ATP5F1D, ATP5F1C | RET 4696/4885LCK 1706/4885SRC 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.